Evidence explorer
Every claim we hold, and how far we can stand behind it.
142 claims across 39 products. 28% are confirmed against the source text by the evidence gate; 39% come from a class with no vendor interest. Everything below is browsable, filterable, and available as JSON.
What this corpus is made of
| Evidence class | Claims | Confirmed | What it can support |
|---|---|---|---|
| Peer-reviewed study | 19 | 5 | Reviewed before publication; assess study quality, funding, conflicts, and relevance to your setting. |
| Regulatory filing | 4 | 0 | A statement made to a regulator, where being wrong has consequences. |
| Independent report | 32 | 9 | Reporting outside a vendor publication; assess underlying data, sponsorship, and conflicts separately. |
| Customer case | 4 | 3 | A real deployment, but selected and framed by someone with an interest. |
| Press release | 63 | 22 | The vendor's own announcement. Useful for dates and facts, not for outcomes. |
| Vendor page | 20 | 1 | Marketing copy. Establishes what is claimed, never that it is true. |
Showing 3 of 3 matching claims (142 in the full corpus) · 67% of this selection is confirmed · clear filters
Received FDA 510(k) clearance and launched the next-generation HeartFlow Plaque Analysis platform in September 2025
Provenance
- Claim ID
- clm_29c575ae0472e53b405e
- Version
- 1
- Workflow
- Imaging & Diagnostic AI
- Dimension
- evidence strength
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://ir.heartflow.com/news-releases/news-release-details/heartflow-announces-fda-510k-clearance-and-launch-next
Completed an upsized IPO on Nasdaq (HTFL) raising ~$364.2M in gross proceeds at $19/share; shares began trading Aug 8, 2025
Provenance
- Claim ID
- clm_6d2284fb4d9b5d1ed5da
- Version
- 1
- Workflow
- Imaging & Diagnostic AI
- Dimension
- market durability
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://ir.heartflow.com/news-releases/news-release-details/heartflow-inc-announces-closing-upsized-initial-public-offering
CEO Prashant Warier states Qure.ai aims to reach profitability in the next financial year and pursue an IPO within roughly two years (May 2025)
Provenance
- Claim ID
- clm_feb6e7535e4e9cab9d13
- Version
- 1
- Workflow
- Imaging & Diagnostic AI
- Dimension
- market durability
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://m.economictimes.com/tech/artificial-intelligence/healthcare-ai-startup-qure-ai-aiming-for-ipo-in-two-years-ceo-says/articleshow/121286035.cms